Table of Contents: Oncotarget’s Volume 12, Issue #20

Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 20.

Oncotarget's Table of Contents

Oncotarget’s Volume 12, Issue #20

New Publications

Listen to an audio version of this post

Cover (Priority Research Paper): Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase

Origin: Rhode Island, United States

Institutions: Brown University, Lifespan Cancer Institute

Quote: “To further investigate the molecular mechanism of HIF-1α destabilization by CDK1 or CDK4/6 inhibitors, we performed a proteomic screen on immunoprecipitated HIF-1α from hypoxic colorectal cancer cells that were either untreated or treated with CDK1 inhibitor Ro3306 and CDK4/6 inhibitor palbociclib.”

Research Paper: A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs

Origin: Rhode Island, United States

Institutions: Brown University, Lifespan Health System

Quote: “The characterization of soluble mediators as biomarkers for diagnosis and prognosis is of interest in oncology. We utilize the cytokinome to characterize the response of colorectal tumor cell lines to selected small-molecules in oncology as a proof-of-concept dataset with immunomodulatory analyte heat map rankings for drug and cell line combinations.”

Research Paper: Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients

Origin: Rhode Island, United States

Institutions: Brown University, Lifespan Health System, Rhode Island Hospital

Quote: “Breast cancer (BC) and colorectal cancer (CRC) are common and show poor survival in advanced stages. Using The Cancer Genome Atlas (TCGA) computational tool cBioPortal, we evaluated overall patient survival in BRCA1 mRNA-low versus -high cohorts (<−1.29 versus >1.05 SD from mean BRCA1 expression, respectively).”

Research Paper: Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells

Origin: Rhode Island, United States

Institutions: Brown University, Lifespan Health System, Rhode Island Hospital

Quote: “Colorectal cancer (CRC) caused over 900,000 deaths worldwide in 2020. A majority of late-stage CRC patients are treated with 5-fluorouracil (5-FU) combined with either irinotecan (CPT-11), oxaliplatin, or both. Despite their widespread use, the mechanisms of efficacy and toxicity of these drugs remain incompletely understood.”

Research Paper: Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Origin: Maryland, Virginia, United States

Institutions: Frederick National Laboratory for Cancer Research, University of Virginia

Quote: “Lung cancer is the leading cause of cancer-related deaths in the USA and worldwide. Yet, about 95% of new drug candidates validated in preclinical phase eventually fail in clinical trials. Such a high attrition rate is attributed mostly to the inability of conventional two-dimensionally (2D) cultured cancer cells to mimic native three-dimensional (3D) growth of malignant cells in human tumors.”

Research Paper: Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma

Origin: Missouri, United States

Institutions: Washington University, Barnes Jewish Hospital

Quote: “Daratumumab (DARA) is an FDA-approved high-affinity monoclonal antibody targeting CD38 that has shown promising therapeutic efficacy in double refractory multiple myeloma (MM) patients. Despite the well-established clinical efficacy of DARA, not all heavily pretreated patients respond to single-agent DARA, and the majority of patients who initially respond eventually progress.”

Research Paper: Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma

Origin: Minnesota, Arizona, United States

Institutions: Mayo Clinic (Minnesota), Mayo Clinic (Arizona)

Quote: “Multiple Myeloma (MM) patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses. Here we evaluate the possibility of adoptive cell transfer (ACT) by generating ex vivo T cells from peripheral blood mononuclear cells (PBMCs) isolated from MM patients by employing our previously devised protocols.”

Research Paper: NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells

Origin: Ohio, California, Oregon, United States

Institutions: The Ohio State University, City of Hope Comprehensive Cancer Center, Oregon Health and Science University

Quote: “Peripheral T-cell lymphoma (PTCL) is characterized by poor outcomes. We and others have shown that targeting the NEDD8-activating enzyme (NAE) with an investigational inhibitor pevonedistat deregulates cell cycle and mitosis in lymphoma and leukemia. Here, we report that PTCL is characterized by increased rate of chromosomal instability.”

Research Paper: Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma

Origin: Florida, United States

Institution: Mayo Clinic (Florida)

Quote: “This study aimed to evaluate the initial safety and efficacy of ablative radioembolization for the treatment of unresectable iCCA [intrahepatic cholangiocarcinoma], in which >75% of the tumor was treated with >190 Gy Medical Internal Radiation Dose (MIRD). An analysis of radioembolization outcomes was performed with respect to tumor blood supply characteristics.”

Review: Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma

Origin: Texas, United States

Institutions: The University of Texas MD Anderson Cancer Center, University of Texas McGovern Medical School, US Dermatology Partners, Baylor College of Medicine

Quote: “This review examines HHI [hedgehog inhibitor] resistance, its underlying mechanisms, and methods of management for patients with advanced BCC [basal cell carcinoma].”

Editorial: Fibrocytes in primary myelofibrosis

Origin: Miyazaki, Japan

Institution: University of Miyazaki

Quote: “More than 80% of PMF [primary myelofibrosis] patients carry mutations that activate the JAK-STAT signaling pathway; about 50%, 25–30%, and 8% of PMF patients harbor JAK2V617F mutations, CALR exon9 frameshift mutations, and myeloproliferative leukemia virus oncogene (MPL) mutations, respectively.”

Research Perspective: Ras-p53 genomic cooperativity as a model to investigate mechanisms of innate immune regulation in gastrointestinal cancers

Origin: Florida, New York, United States

Institutions: University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center,

Quote: “Despite increasingly thorough mechanistic understanding of the dominant genetic drivers of gastrointestinal (GI) tumorigenesis (e.g., Ras/Raf, TP53, etc.), only a small proportion of these molecular alterations are therapeutically actionable. In an attempt to address this therapeutic impasse, our group has proposed an innovative extreme outlier model to identify novel cooperative molecular vulnerabilities in high-risk GI cancers which dictate prognosis, correlate with distinct patterns of metastasis, and define therapeutic sensitivity or resistance.”

Click here to read Oncotarget’s Volume 12, Issue #20.

YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube

Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.

For media inquiries, please contact

Leave a Reply

Your email address will not be published. Required fields are marked *